“ A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients ”, Clinics, vol. 71, no. 10, pp. 586–592, Oct. 2016, doi: 10.6061/clinics/2016(10)06.